A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Investigator: Monisha Singh, MD

Study Coordinator: Caroline Fitzgerald

Status: Enrolling

ClinicalTrials.gov Number: NCT04068896

Phone: 713.441.3250

Protocol Number: PRO00024662


NGM120 is an experimental drug made by NGM Biopharmaceuticals, Inc. NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer. The purpose of this study is to find out what effects, both good and/or bad, of the study drug “NGM120”, as well as the combination of NGM120 and standard therapy (gemcitabine and Abraxane) may have subjects and their type of cancer and your cancer-associated loss of appetite, weight loss and loss of muscle.
More to Explore